|
US4309406A
(en)
|
1979-07-10 |
1982-01-05 |
American Home Products Corporation |
Sustained release pharmaceutical compositions
|
|
US4309404A
(en)
|
1979-08-09 |
1982-01-05 |
American Home Products Corporation |
Sustained release pharmaceutical compositions
|
|
US4556552A
(en)
|
1983-09-19 |
1985-12-03 |
Colorcon, Inc. |
Enteric film-coating compositions
|
|
US4704295A
(en)
|
1983-09-19 |
1987-11-03 |
Colorcon, Inc. |
Enteric film-coating compositions
|
|
IL73883A
(en)
|
1984-12-20 |
1990-12-23 |
Yeda Res & Dev |
Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
|
|
US5235033A
(en)
|
1985-03-15 |
1993-08-10 |
Anti-Gene Development Group |
Alpha-morpholino ribonucleoside derivatives and polymers thereof
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
US4666829A
(en)
|
1985-05-15 |
1987-05-19 |
University Of California |
Polypeptide marker for Alzheimer's disease and its use for diagnosis
|
|
US5580774A
(en)
|
1989-07-31 |
1996-12-03 |
Eli Lilly And Company |
Chimeric antibodies directed against a human glycoprotein antigen
|
|
WO1991006556A1
(en)
|
1989-10-24 |
1991-05-16 |
Gilead Sciences, Inc. |
2' modified oligonucleotides
|
|
SG88714A1
(en)
|
1989-11-06 |
2002-05-21 |
Cell Genesys Inc |
Production of proteins using homologous recombination
|
|
DE779362T1
(de)
|
1989-12-22 |
2001-04-05 |
Applied Research Systems Ars Holding N.V., Curacao |
DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen
|
|
US5272071A
(en)
|
1989-12-22 |
1993-12-21 |
Applied Research Systems Ars Holding N.V. |
Method for the modification of the expression characteristics of an endogenous gene of a given cell line
|
|
US5223618A
(en)
|
1990-08-13 |
1993-06-29 |
Isis Pharmaceuticals, Inc. |
4'-desmethyl nucleoside analog compounds
|
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
|
JPH0874B2
(ja)
|
1990-07-27 |
1996-01-10 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
|
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5378825A
(en)
|
1990-07-27 |
1995-01-03 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US5177196A
(en)
|
1990-08-16 |
1993-01-05 |
Microprobe Corporation |
Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
|
|
AU652997B2
(en)
|
1991-01-21 |
1994-09-15 |
Elan Pharmaceuticals, Inc. |
Test and model for alzheimer's disease
|
|
US5672697A
(en)
|
1991-02-08 |
1997-09-30 |
Gilead Sciences, Inc. |
Nucleoside 5'-methylene phosphonates
|
|
DE07012626T1
(de)
|
1991-03-18 |
2010-01-21 |
New York University |
Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
|
|
AU664847B2
(en)
|
1991-05-15 |
1995-12-07 |
Cell Genesys, Inc. |
Genomic modifications with homologous DNA targeting
|
|
NZ245015A
(en)
|
1991-11-05 |
1995-12-21 |
Transkaryotic Therapies Inc |
Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
|
|
CA2142300C
(en)
|
1992-10-13 |
2005-08-23 |
Allen D. Roses |
Methods for detecting alzheimer's disease
|
|
TW402639B
(en)
|
1992-12-03 |
2000-08-21 |
Transkaryotic Therapies Inc |
Protein production and protein delivery
|
|
US5858988A
(en)
|
1993-02-24 |
1999-01-12 |
Wang; Jui H. |
Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
|
|
WO1995000649A1
(en)
|
1993-06-25 |
1995-01-05 |
Smithkline Beecham Plc |
Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy
|
|
EP1096016B1
(en)
|
1993-10-06 |
2006-01-11 |
Icos Corporation |
Platelet-activating factor acetylhydrolase
|
|
US5519134A
(en)
|
1994-01-11 |
1996-05-21 |
Isis Pharmaceuticals, Inc. |
Pyrrolidine-containing monomers and oligomers
|
|
GB9421816D0
(en)
|
1994-10-29 |
1994-12-14 |
Smithkline Beecham Plc |
Novel compounds
|
|
WO1996019451A1
(en)
|
1994-12-22 |
1996-06-27 |
Smithkline Beecham Plc |
Substituted azetidin-2-ones for treatment of atherosclerosis
|
|
HUP9901153A3
(en)
|
1995-07-01 |
1999-11-29 |
Smithkline Beecham Plc |
Azetidinone derivatives for the treatment of atherosclerosis, their production and pharmaceutical compositions containing them
|
|
US5705629A
(en)
|
1995-10-20 |
1998-01-06 |
Hybridon, Inc. |
Methods for H-phosphonate synthesis of mono- and oligonucleotides
|
|
EP0865429A1
(en)
*
|
1995-12-08 |
1998-09-23 |
Smithkline Beecham Plc |
Azetidinone compounds for the treatment of atherosclerosis
|
|
EP0869943A1
(en)
|
1995-12-08 |
1998-10-14 |
Smithkline Beecham Plc |
Monocyclic beta-lactame derivatives for treatment of atherosclerosis
|
|
GB9608649D0
(en)
|
1996-04-26 |
1996-07-03 |
Smithkline Beecham Plc |
Novel compounds
|
|
CZ341098A3
(cs)
|
1996-04-26 |
1999-03-17 |
Smithkline Beecham Plc |
Azetidinonové deriváty pro ošetřování aterosklerózy
|
|
WO1999024420A1
(en)
|
1997-11-06 |
1999-05-20 |
Smithkline Beecham Plc |
Pyrimidinone compounds and pharmaceutical compositions containing them
|
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
DE69911980T2
(de)
|
1998-08-21 |
2004-09-09 |
Smithkline Beecham P.L.C., Brentford |
Pyrimidinonderivate zur behandlung von atheroscleros
|
|
GB9910079D0
(en)
|
1999-05-01 |
1999-06-30 |
Smithkline Beecham Plc |
Novel compounds
|
|
DE60042286D1
(de)
|
1999-05-01 |
2009-07-09 |
Smithkline Beecham Plc |
Pyrimidinon Verbindungen
|
|
GB9910378D0
(en)
|
1999-05-05 |
1999-06-30 |
Smithkline Beecham Plc |
Novel compounds
|
|
DE60139429D1
(de)
|
2000-02-16 |
2009-09-10 |
Smithkline Beecham Plc |
Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren
|
|
JP2003526367A
(ja)
|
2000-03-16 |
2003-09-09 |
ジェネティカ インコーポレイテッド |
Rna干渉の方法とrna干渉組成物
|
|
WO2007028133A2
(en)
|
2005-08-30 |
2007-03-08 |
Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Treatment and prevention of vascular dementia
|
|
US7107092B2
(en)
|
2000-08-21 |
2006-09-12 |
The General Hospital Corporation |
Methods for diagnosing a neurodegenerative condition
|
|
GB0024807D0
(en)
|
2000-10-10 |
2000-11-22 |
Smithkline Beecham Plc |
Novel compounds
|
|
GB0024808D0
(en)
|
2000-10-10 |
2000-11-22 |
Smithkline Beecham Plc |
Novel compounds
|
|
AU2002248224B2
(en)
|
2000-10-27 |
2006-11-09 |
Baylor College Of Medicine |
Methods and compositions for the identification and treatment of neurodegenerative disorders
|
|
US6884591B2
(en)
|
2001-06-25 |
2005-04-26 |
The Cleveland Clinic Foundation |
Peripheral marker of blood brain barrier permeability
|
|
GB0119793D0
(en)
*
|
2001-08-14 |
2001-10-03 |
Smithkline Beecham Plc |
Novel compounds
|
|
GB0119795D0
(en)
|
2001-08-14 |
2001-10-03 |
Smithkline Beecham Plc |
Novel process
|
|
GB0127140D0
(en)
*
|
2001-11-10 |
2002-01-02 |
Smithkline Beecham |
Novel compounds
|
|
GB0127143D0
(en)
|
2001-11-10 |
2002-01-02 |
Smithkline Beecham |
Novel compounds
|
|
GB0127139D0
(en)
|
2001-11-10 |
2002-01-02 |
Smithkline Beecham |
Novel compounds
|
|
GB0127141D0
(en)
|
2001-11-10 |
2002-01-02 |
Smithkline Beecham Plc |
Novel compounds
|
|
GB0208279D0
(en)
|
2002-04-10 |
2002-05-22 |
Glaxo Group Ltd |
Novel compounds
|
|
GB0208280D0
(en)
|
2002-04-10 |
2002-05-22 |
Glaxo Group Ltd |
Novel compounds
|
|
AU2003248660A1
(en)
|
2002-06-11 |
2003-12-22 |
Socratech, L.L.C. |
Treatment of vascular dysfunction and alzheimer's disease
|
|
US20060241130A1
(en)
*
|
2003-01-31 |
2006-10-26 |
Ehud Keinan |
Anti-inflammatory compositions and uses thereof
|
|
CA2435538A1
(en)
|
2003-07-18 |
2005-01-18 |
Universite Laval |
Solvent resistant asymmetric integrally skinned membranes
|
|
GB0320522D0
(en)
|
2003-09-02 |
2003-10-01 |
Glaxo Group Ltd |
Formulation
|
|
US20050108779A1
(en)
|
2003-10-21 |
2005-05-19 |
Envivo Pharmaceuticals, Inc. |
Transgenic flies expressing Abeta42-Italian
|
|
US20040255342A1
(en)
|
2003-10-21 |
2004-12-16 |
Envivo Pharmaceuticals, Inc. |
Transgenic flies expressing Abeta42-Iowa
|
|
US20040250302A1
(en)
|
2003-10-21 |
2004-12-09 |
Envivo Pharmaceuticals, Inc. |
Transgenic flies expressing Abeta42-dutch
|
|
US20040244064A1
(en)
|
2003-10-20 |
2004-12-02 |
Envivo Pharmaceuticals, Inc. |
Transgenic flies expressing Abeta42-Flemish
|
|
US20050132423A1
(en)
|
2003-10-20 |
2005-06-16 |
Envivo Pharmaceuticals, Inc. |
Transgenic flies expressing Abeta42-Flemish
|
|
US20040255341A1
(en)
|
2003-10-21 |
2004-12-16 |
Envivo Pharmaceuticals, Inc. |
Transgenic flies expressing Abeta42-Arctic
|
|
US20050132424A1
(en)
|
2003-10-21 |
2005-06-16 |
Envivo Pharmaceuticals, Inc. |
Transgenic flies expressing Abeta42-Dutch
|
|
US20050132421A1
(en)
|
2003-10-21 |
2005-06-16 |
Envivo Pharmaceuticals, Inc. |
Transgenic flies expressing Abeta42-Arctic
|
|
US20050132422A1
(en)
|
2003-10-21 |
2005-06-16 |
Envivo Pharmaceuticals, Inc. |
Transgenic flies expressing Abeta42-Iowa
|
|
KR100784337B1
(ko)
|
2004-11-12 |
2007-12-13 |
한국생명공학연구원 |
신규한 o-아실옥심 유도체, 그의 제조방법 및 이를유효성분으로 하는 심장순환계 질환의 예방 및 치료용약학 조성물
|
|
DE102004061006A1
(de)
|
2004-12-18 |
2006-06-22 |
Bayer Healthcare Ag |
3-Benzylthio-1,2,4-triazin-5(2H)-one
|
|
DE102004061009A1
(de)
|
2004-12-18 |
2006-06-22 |
Bayer Healthcare Ag |
Substituierte 1,2,4-Triazin-5(2H)-one
|
|
DE102004061005A1
(de)
|
2004-12-18 |
2006-06-22 |
Bayer Healthcare Ag |
3-Cycloalkyl-1,2,4-triazin-5(2H)-one
|
|
DE102004061008A1
(de)
|
2004-12-18 |
2006-06-22 |
Bayer Healthcare Ag |
3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one
|
|
US20060280748A1
(en)
*
|
2005-04-22 |
2006-12-14 |
Buckheit Robert W Jr |
Plasma or serum fraction for treatment or prevention of abnormal cell proliferation
|
|
AU2006242651B2
(en)
*
|
2005-04-29 |
2013-05-16 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
WO2007029081A1
(en)
*
|
2005-09-05 |
2007-03-15 |
Ranbaxy Laboratories Limited |
Galantamine-containing controlled release oral dosage forms, processes for the preparation thereof and use for the manufacture of a medicament
|
|
WO2008048867A2
(en)
*
|
2006-10-13 |
2008-04-24 |
Glaxo Group Limited |
Bicyclic heteroaromatic compounds
|